Trials / Completed
CompletedNCT05415969
CKD-aP Among Adults on Dialysis in Switzerland
Uremic Pruritus Among Adults on Dialysis in the French Speaking Part of Switzerland
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 401 (actual)
- Sponsor
- University of Applied Sciences of Western Switzerland · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Chronic Kidney Disease Associated Pruritus (CKD-aP) represents a localized or a generalized skin itch, which is a common symptom occurring in end-stage renal disease and dialysis. The prevalence of CKD-aP in adults on dialysis varies between countries ranging between 20-42%. Swiss data on CKD-aP are unfortunately largely lacking, as Switzerland is so far not part of large registries, such as DOPPS. The aging population, the increase in diabetes (69% by 2030), the increase in hypertension (60% by 2025) and poly-morbidity will probably lead to a rise in the number of patients on dialysis and subsequent CKD-aP. CKD-aP is associated with sleep disturbances, compromised quality of life, emotional distress, and increased risks of hospitalization and death. Its management lacks approaches that are supported by strong evidence because its pathogenesis remains poorly understood and may be related to an increase in uremic toxins, skin inflammation. In this context, sweat composition deserves more attention. Aim of the study The aim of the study is to determine the prevalence of CKD-aP in the population on dialysis, the association between CKD-aP and different electrolytes, and the potential role of the composition of sweat in CKD-aP. Results will be used for building a CKD-aP symptom management program to improve the quality of care of patients on dialysis and will be incorporated in the nursing continuing education program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | CKD-aP | Identification of CKD-aP prevalence and severity among patients on dialysis. |
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2023-10-09
- Completion
- 2023-10-09
- First posted
- 2022-06-13
- Last updated
- 2023-11-18
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT05415969. Inclusion in this directory is not an endorsement.